Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics (PLRX)
NASDAQ:PLRX
RESEARCH TOOLSreports
PLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.43 - $18.00
Previous CloseN/A
Volume34.91K
Average Volume (3M)2.35M
Market Cap
$183.17M
Enterprise Value$336.49M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Mar 04, 2025EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.34
Shares Outstanding60,853,622
10 Day Avg. Volume6,029,757
30 Day Avg. Volume2,348,480
Standard Deviation0.26
R-Squared0.04
Alpha-0.00877
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)115.54
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit212.97
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$14.00Price Target Upside354.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Market ReactionPLRX shares are up +25% on the news, reflecting a measured level of optimism for the trial to resume dosing.
Trial EvaluationPLRX is assembling an outside panel of experts to review unblinded data from the Phase 2b BEACON-IPF trial and subsequently reach a consensus recommendation with the DSMB on a path forward for the trial.
Bears Say
Safety ConcernsEnrollment and dosing in the BEACON-IPF trial were paused due to a recommendation from the independent Data Safety Monitoring Board.
UncertaintyThere is a high degree of uncertainty regarding the company's primary asset, leading to the withholding of a price target.
---
Ownership Overview
4.40% Insiders
19.84% Mutual Funds
0.50% Other Institutional Investors
63.51% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PLRX FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was $2.43 and its highest was $18.00 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Pliant Therapeutics’s market cap is $183.17M.
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 10 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$0.969 by $0.019.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -0.98.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 60,853,622 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$0.969. Following the earnings report the stock price went down -1.251%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Currently, no hedge funds are holding shares in PLRX
---
Pliant Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (354.55% Upside)
$14.00 (354.55% Upside)
Blogger Sentiment
Bullish
PLRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 45.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.64%
12-Months-Change
Fundamentals
Return on Equity
-47.52%
Trailing 12-Months
Asset Growth
-17.54%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
---
PLRX Stock 12 Month Forecast
Average Price Target
$14.00
▲(354.55% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Nektar Therapeutics
―
Vertex Pharmaceuticals
―
Blueprint Medicines
―
Galapagos
―
Best Analysts Covering PLRX
1 Year
1 Year Success Rate
8/25 ratings generated profit
1 Year Average Return
-2.94%
reiterated a buy rating 10 days ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 32.00% of your transactions generating a profit, with an average return of -2.94% per trade.
---